Adaptive Biotechnologies Corporation (ADPT)

Market Cap	378.69M
Revenue (ttm)	170.28M
Net Income (ttm)	-225.25M
Shares Out	145.09M
EPS (ttm)	-1.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,807,175
Open	2.540
Previous Close	2.600
Day's Range	2.480 - 2.640
52-Week Range	2.280 - 9.080
Beta	1.24
Analysts	Buy
Price Target	6.80 (+160.54%)
Earnings Date	May 7, 2024

About ADPT

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as M...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 27, 2019
• Employees: 709
• Stock Exchange: NASDAQ
• Ticker Symbol: ADPT

Financial Performance

In 2023, ADPT's revenue was $170.28 million, a decrease of -8.11% compared to the previous year's $185.31 million. Losses were -$225.25 million, 12.5% more than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for ADPT stock is "Buy." The 12-month stock price forecast is $6.8, which is an increase of 160.54% from the latest price.

Price Target

$6.8

(160.54% upside)

Analyst Consensus: Buy